WO2007043302A1 - インスリン抵抗性改善剤 - Google Patents
インスリン抵抗性改善剤 Download PDFInfo
- Publication number
- WO2007043302A1 WO2007043302A1 PCT/JP2006/318809 JP2006318809W WO2007043302A1 WO 2007043302 A1 WO2007043302 A1 WO 2007043302A1 JP 2006318809 W JP2006318809 W JP 2006318809W WO 2007043302 A1 WO2007043302 A1 WO 2007043302A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin resistance
- compound
- insulin
- present
- extract
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
Definitions
- the present invention relates to an insulin resistance ameliorating agent containing 3-O-l ⁇ -D-Dalcoviranosyl 4-methylergosto 7-en-en 3 ol as an active ingredient, and a food and drink containing the same . More specifically, free fatty acids, plasminogen activation inhibitor, tumor necrosis factor, monosite 'chemoatractant' protein 1-1, resistin, etc., which are factors involved in the onset and seriousness of pathologies related to insulin resistance Relates to an insulin resistance ameliorating agent having an effect of regulating the production of adipocyte power in and foods and beverages containing the same
- Insulin is a type of hormone produced from ⁇ cells in the prestigious islets of Langerhans (Lai Island), and is responsible for insulin receptors present in insulin target tissues such as skeletal muscle, liver, and fat. Therefore, it acts not only on sugar metabolism but also on lipid metabolism and protein metabolism, and plays an important role in maintaining the homeostasis of the living body.
- the action of insulin in each target tissue includes the uptake of glucose in blood into muscle cells and adipocytes, the promotion of glycogen production in the liver and muscle tissue, the suppression of gluconeogenesis in the liver, the glucose in adipocytes Examples include promotion of consumption and fatty acid synthesis, and suppression of lipid degradation.
- Insulin resistance is a state in which more than a normal amount of insulin is required to obtain various actions of insulin at the cellular, S-vessel, and individual levels, that is, an insulin dysfunction state in which sensitivity to insulin is reduced. That's it. From the results of previous epidemiological studies, hypertension, diabetes, hyperlipidemia (hypertriglyceridemia, low HDL cholesterolemia), hypertrophy, etc. are considered to be pathologies based on insulin resistance. Insulin resistance leads to insufficient insulin action in glucose metabolism, resulting in compensatory hyperinsulinemia to maintain blood glucose, leading to hyperglycemia and impaired glucose tolerance, as well as diabetes due to knee cell exhaustion. Progresses.
- Hyperinsulinemia is also associated with increased sympathetic nerve activity and sodium absorption in the kidneys to develop hypertension, as well as postprandial hyperlipidemia and hyperuremia. It also induces acidemia and increased plasminogen activity inhibitor (PAI-1 plasminogen activator inhibitor -1).
- adipose tissue is not a simple energy storage tissue. Recognized as the largest endocrine organ in the body. These endocrine factors derived from adipose tissue are collectively referred to as adipocyte force-in and play an important role in maintaining homeostasis in metabolism. 'Insulin resistance is thought to be caused by over- or under-secretion and disruption of balance.
- adipocyte-inducing agents that increase insulin sensitivity and those that induce insulin resistance.
- Typical examples of the former include adiponectin, leptin, and AM PK (AMP-dependent protein kinase). It has been known.
- adiponectin has been reported to release insulin resistance and suppress gluconeogenesis in the liver (Non-patent Document 2).
- tumor necrosis factor in addition to the above-mentioned FFA and P AI _1, in addition to the above-mentioned FFA and P AI _1, tumor necrosis factor (TNF—hi); inflammatory chemokine Examples are monosites, chemoretractants, protein 1 (MCP-1; monocyte c hemoattractant protein-1) and resistin.
- TNF-a is an insulin receptor and IRS 1 (insulin receptor subs) in the insulin signaling mechanism. A mechanism of action has been reported that induces insulin resistance by inhibiting trate phosphorylation of trate 1) and attenuating insulin action.
- MCP-1 is considered to be a causative substance that decreases insulin sensitivity (Non-patent Documents 3, 4, and 5).
- an insulin resistance ameliorating agent (patent document 1) containing adiponectin or a gene thereof as an active ingredient, a substance having affinity for bombesin receptor subtype 3 (BRS-3) Insulin resistance is a prophylactic and / or therapeutic agent for diseases caused by insulin resistance (Patent Document 2), and a free fatty acid (FFA) reducing agent (Patent Document 3) containing pyrrole derivatives as active ingredients. It is disclosed as a property improving agent. Furthermore, it contains a food-derived substance as an active ingredient, and contains an insulin resistance improving composition containing acetic acid and its ions or salts as an active ingredient (Patent Document 4), a specific diglyceride and Z or monoglyceride. Insulin resistance improving agents composed of fats and oils (Patent Document 5) and the like are disclosed.
- Plant sterols such as ⁇ -sitosterol, campesterol, and stigmasterol are already known to have an effect of lowering blood cholesterol by inhibiting absorption of cholesterol, and are put into practical use such as being added to edible oils as an oil and fat composition. Has been done.
- synthesis of plant sterols such as ⁇ -sitosterol and campesterol as starting materials
- Anti-obesity agents and lipid metabolism improving agents containing S. cholestenone compounds as active ingredients are disclosed (Patent Documents 6 to 8, Non-Patent Document 6).
- Aloe vera Aloe barbadenisis Miller
- Patent Document 10 an immunosuppression improving agent characterized by containing a butanol fraction or a mouth-in of an aloe extract (Patent Document 10), an agent for improving blood glucose level (Patent Documents 11 to 14), and obesity
- Patent Document 15 an agent for improving blood glucose level
- Patent Document 1 International Publication 2003/63894 Pamphlet
- Patent Document 2 JP-A-10-298100
- Patent Document 3 JP-A-8-12573
- Patent Document 4 Japanese Unexamined Patent Application Publication No. 2002-193797
- Patent Document 5 JP 2001-247473 A
- Patent Document 6 Japanese Patent Laid-Open No. 7-165587
- Patent Document 7 Japanese Patent Laid-Open No. 11 193296
- Patent Document 8 Japanese Patent Laid-Open No. 2001-240544
- Patent Document 9 Japanese Patent Laid-Open No. 2005-68132
- Patent Document 10 JP-A-8-208495
- Patent Document 11 JP 59-214741
- Patent Document 12 Japanese Unexamined Patent Publication No. 2003-286185
- Patent Document 13 US Patent No. 4598069
- Patent Document 14 US Patent Application Publication No. 2003/0207818
- Patent Document 15 Japanese Unexamined Patent Publication No. 2000-319190
- Non-patent document 1 Insulin resistance and lifestyle-related diseases, edited by Kazuaki Shimamoto, Diagnosis and Treatment, 2003, No .: pp.-5
- Non-Patent Document 2 Adiposcience, No. 1, No. 3, 2004, pp. 247-257
- Non-Patent Document 3 Proceedings ⁇ National ⁇ Academia 1'b ⁇ Sciences ( ⁇ ⁇ 0 ceedings of the National Academy of Sciences), 100th, 2003, 7265-72 70
- Non-Patent Document 4 Nature, 389, 1997, 610-614
- Non-Patent Document 5 The Netherlands Journal of Medicine, The Netherlands Journal of Medicine, Vol. 6, No. 6, 2003, pp. 194-212
- Non-Patent Document 6 Hormone 'Metabolism' Research, 37th, 2005, pp. 79-83
- the biguanide agent which is a conventional drug that improves insulin resistance, sometimes causes gastrointestinal disorders and rarely lactic acidosis.
- thiazolidine derivatives the same drug, may cause serious side effects such as body fluid retention, weight gain, and liver dysfunction.
- diabetic drugs it has been difficult to use diabetic drugs in practice for insulin resistance in a condition that is not diabetes or hyperglycemia. Under such circumstances, there has been a strong demand for the development of functional materials that are safe, can be taken on a daily basis, and can efficiently improve insulin resistance without causing pain as much as possible.
- the present inventors have found that insulin resistance leading to lifestyle-related diseases such as hypertension, diabetes, hyperlipidemia (hypertriglyceridemia, low HDL cholesterolemia), obesity, etc.
- lifestyle-related diseases such as hypertension, diabetes, hyperlipidemia (hypertriglyceridemia, low HDL cholesterolemia), obesity, etc.
- drugs related to the mechanism and prevention / improvement of diseases i.e., insulin resistance improvers
- adipocyte power-in which is a factor involved in the onset and seriousness of insulin resistance.
- 3-O- ⁇ D-Dalcoviranosyl 4-methylergosto 7-en-3-ol was free fat.
- Patent Document 9 shows only the effect of preventing differentiation of cultured adipocytes of the above-mentioned plant extract and the promotion of secretion of ergosterol adiponectin. There was no description or suggestion regarding the insulin resistance improving action of the active ingredient of the present invention.
- An object of the present invention is to provide the above 3-0- ⁇ D darcoviranosyl-4-methylergost
- Another object of the present invention is to provide a functional food or drink such as a food for specified health use containing the insulin resistance improving agent.
- a first invention of the present application for solving the above-mentioned problems is an insulin resistance improving agent comprising a compound represented by the following chemical formula (1) as an active ingredient.
- the second invention of the present application for solving the above-mentioned problems is a plant organic solvent extract, a hot water extract, or a pressed solution containing a compound represented by the following chemical formula (1), or a fraction thereof:
- An insulin resistance-improving agent comprising: a plant organic solvent extract, a hot water extract, a compressed solution, or a fraction thereof, wherein the compound represented by the following chemical formula (1)
- the insulin resistance improving agent contains a composition containing at least 0.001% by mass as an active ingredient, and the plant is a lily family plant.
- a third invention of the present application for solving the above-mentioned problems is a food or drink containing the insulin resistance improving agent according to the first or second invention, wherein the compound represented by the chemical formula (1) is 0 It is a preferable aspect to contain 0001% by mass or more.
- the fourth invention of the present application for solving the above-mentioned problems is that the compound represented by the chemical formula (1) for the production of an insulin resistance improving agent, or the compound is at least 0.001% by mass in dry mass. It is the use of an organic solvent extract, a hot water extract, a pressed solution, or a fraction thereof containing the plant, wherein the plant is a lily family plant.
- a fifth invention of the present application for solving the above-mentioned problems is a method for improving insulin resistance, wherein the compound represented by the chemical formula (1) or the compound is at least 0.001% by mass in dry mass.
- a method comprising administering an organic solvent extract, a hot water extract, a compressed solution, or a fraction thereof containing a plant to a subject to improve insulin resistance.
- a preferred embodiment is a lily family plant.
- the insulin resistance-improving agent of the present invention and food and drink containing the same can be safely administered or ingested, and have a preventive effect on lifestyle-related diseases that are considered to be caused by insulin resistance.
- the active ingredient of the insulin resistance improving agent of the present invention can be easily produced from a lily family plant such as Aloe barbadensis Miller that can be safely ingested and easily obtained from dietary experience.
- FIG. 1 is a diagram showing changes in blood glucose levels in an insulin tolerance test.
- the insulin resistance improving action is an action for preventing or improving various health hazards, for example, lifestyle-related diseases, etc. that are induced by a decrease in insulin sensitivity.
- PAI 1 plasminogen activation inhibitory factor
- FFA free fatty acid
- TNF tumor necrosis factor
- MCP which are effective in preventing or improving the onset and severity of pathologies related to insulin resistance — 1.
- Effectively suppresses the increase or production of adipocyte power-in that induces insulin resistance such as resistin, hyperinsulinemia, hyperlipidemia, impaired glucose tolerance, diabetes, hypertension, obesity, arteriosclerosis, etc.
- the insulin resistance improving agent of the present invention can be defined as an insulin sensitivity enhancer, an adipocyte force-in production regulator, particularly an adipocyte force-in production inhibitor that induces insulin resistance.
- Insulin resistance can be assessed by glucose clamp method, SSPG (Steady state plasma glucose) method, minimal model method, HOMA-IR (homeostasis model assessment) based on fasting blood glucose level and blood insulin concentration.
- (insulin resistance) index is exemplified by a method for determining half-lj and an insulin tolerance test (insulin tolerance test), and any method can evaluate insulin resistance.
- insulin resistance It is preferable to use an insulin tolerance test (insulin tolerance test) using animals, which is not affected by secretory capacity and can directly examine insulin sensitivity.
- the compound having the structure represented by the chemical formula (1) has an action of increasing insulin sensitivity, and as a result, it is possible to prevent or ameliorate a pathological condition caused by insulin resistance. Therefore, it can be used as an effective component of an insulin resistance improving agent or a food or drink containing the same. Insulin sensitivity can also be evaluated by measuring the blood glucose level lowering response after insulin administration.
- a compound (hereinafter also referred to as “the compound of the present invention”) used as an active ingredient of the insulin resistance improving agent of the present invention (hereinafter also referred to as “the pharmaceutical of the present invention”) is represented by the chemical formula (1). It is a compound having the structure represented, namely 3—O 1 ⁇ D darcoviranosyl-4-methylergost-7-en-3-ol.
- the compound of the present invention has a structure in which the hydroxyl group at the 3-position of 4-methylergost-7-en-3-ol and the hydroxyl group at the 1-position of D_glucose are dehydrated and condensed.
- the purity of the compound of the present invention used as an active ingredient of the insulin resistance ameliorating agent of the present invention is most preferably 100%, but is appropriately set within a range having an action of improving insulin resistance. Is possible.
- a composition used as an active ingredient of the insulin resistance improving agent of the present invention contains at least 0.001 of the compound of the present invention in a dry mass.
- the upper limit of the content of the compound of the present invention is not particularly limited, but 10% by mass is preferably 50% by mass, 70% by mass, or 90% by mass.
- the dry mass means the 14th revised Japanese Pharmacopoeia (March 30, 2001).
- the compound of the present invention or a composition containing the same belongs to, for example, a lily family plant, and a fraction containing the compound is removed from the plant containing the compound of the present invention or a part thereof or a crushed product thereof with an organic solvent. Alternatively, it can be manufactured by extracting and concentrating with hot water.
- Examples of the plant belonging to the lily family include plants belonging to the genus Aloe or Allium. Aloe vera plants (Aloe barbadensis Miller), Aloe fex rocks mirror (Aloe ferox Miller), Aloe africana Miller, Aloe africana Miller, Aloe arborescen Miller var. Natalensis Berger, Aloe spicata Examples include Aloe spicata Baker. In the production of the compound of the present invention or a composition containing the same, the whole plant may be used, but it is preferable to use mesophyll (transparent gel portion).
- mesophyll transparent gel portion
- Such a plant or a part thereof is preferably crushed and liquefied using a homogenizer or the like, and extracted with an organic solvent or hot water.
- organic solvent include alcohols such as methanol, ethanol and butanol; esters such as methyl acetate, ethyl acetate, propyl acetate, and butyl acetate; ketones such as acetone and methyl isobutyl ketone; ethers such as jetyl ether and petroleum ether; hexane, Hydrocarbons such as cyclohexane, toluene, benzene, etc .; Halogenated hydrocarbons such as carbon tetrachloride, dichloromethane, chloroform, etc .; Heterocyclic compounds such as pyridine, Dalicol such as ethylene glycol; Polyalcohols such as polyethylene glycol; Acetonitrile And nitrile solvents such as these, and mixtures of these solvents. These solvents may
- an extraction method a method used for extraction of normal plant components can be used. Usually, 1 to 300 parts by mass of an organic solvent is used per 1 part by mass of a fresh or dried plant, and the mixture is heated to reflux at a temperature not higher than the boiling point of the solvent while stirring or shaking, or is subjected to ultrasonic extraction at room temperature. A method is mentioned.
- the crude extract can be obtained by separating the insoluble matter by an appropriate method such as filtration or centrifugation.
- the crude extract can be purified by various chromatographic methods such as normal phase or reverse phase silica gel column chromatography.
- the compound obtained as described above or the compositional power comprising the same causes, for example, an insulin resistance improving action or insulin resistance by the method described in the Examples below. It is possible to confirm the effect of inhibiting the production of adipocyte power in For example, a glycoside in which glucose is bound to the aglycone part, and that the aglycon part is 4-methylergosto-1-en-3-ol is shown by 13 C-nuclear magnetic resonance spectroscopy (NMR). Etc. can be confirmed.
- NMR 13 C-nuclear magnetic resonance spectroscopy
- the compound of the present invention can also be produced by condensing D-glucose and 4-methylergost-7en-3ol.
- 4-Methylergost 7-en_3_ol can be obtained from plants by extraction and purification. The condensation of D-glucose with 4-methylergost-7_en-3_ol is shown, for example, in 4th edition Experimental Chemistry Course 26, 1992 (described on pages 272, 297 and 342, respectively) This method can be performed in combination. In other words, after completely acetylating D-gnolecose, the anomeric position is converted into a monobromide.
- the compound of the present invention can be used as it is as the active ingredient of the insulin resistance-improving agent of the present invention or a food or drink containing the same.
- an organic solvent extract, a hot water extract, or a pressed solution of a plant or a fraction thereof (hereinafter referred to as “extract etc.”) containing the compound of the present invention is an insulin resistance improving agent.
- the squeezed solution is a product obtained by collecting a plant squeezed stock solution by applying a pulverized plant to a squeezing machine, and removing an insoluble fraction (foreign matter) using a filter or cloth.
- a pulverized plant foreign matter
- an insoluble fraction foreign matter
- An aloe vera squeezed solution can be prepared by removing foreign matter using a filter or cloth.
- the total content of alloin and aloe emodin contained in the outer skin of aloe vera leaves is preferably 5 ppm or less.
- the extract or the like to be contained in the insulin resistance improving agent contains at least 0.001% by mass of the compound of the present invention in dry mass. It is particularly preferable to contain 0.05 to 1% by mass. In addition, it is preferable that the extract or the like contained in the food or drink product contains at least 0.001% by mass of the compound of the present invention in a dry mass of 0.001 to 1% by mass. It is particularly preferable to contain 0.005 to 1% by mass.
- the extract or the like may be a solution and can be stored or used as a powder by freeze-drying or spray-drying by a conventional method.
- the insulin resistance ameliorating agent of the present invention is a composition of the present invention or an extract containing the same as it is or in combination with a pharmaceutically acceptable pharmaceutical carrier, orally, or It can be administered parenterally to mammals including humans.
- the compound of the present invention can be converted to a pharmaceutically acceptable salt.
- Pharmaceutically acceptable salts include both metal salts (inorganic salts) and organic salts, a list of which is listed in “Remington's Pharmaceutical Sciences”, 17th edition, no. 1418, 1985 " Is exemplified.
- inorganic acid salts such as hydrochloride, sulfate, phosphate, diphosphate and hydrobromide, malate, maleate, fumarate, tartrate, succinate,
- Organic salts such as citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, pamoate, salicylate and stearate are included without limitation.
- it may be a salt of a metal such as sodium, potassium, calcium, magnesium or aluminum, or a salt with an amino acid such as lysine.
- solvates such as hydrates of the above compounds or pharmaceutically acceptable salts thereof are also included in the present invention.
- the preparation form of the insulin resistance-improving agent of the present invention is not particularly limited and can be appropriately selected depending on the therapeutic purpose. Specifically, tablets, pills, powders, solutions, suspensions, emulsions, granules Agents, strengths, pushells, syrups, suppositories, injections, ointments, patches, eye drops, nasal drops and the like.
- Additives such as solvents can be used.
- the compound of the present invention or an extract containing the same may be used in combination with other drugs having an insulin resistance improving action.
- the amount of the compound of the present invention or the extract containing the compound contained in the insulin resistance-improving agent of the present invention is not particularly limited and may be appropriately selected.
- the amount of the compound of the present invention In the preparation it should be at least 0.001% by mass, preferably 0.01-:!% By mass, particularly preferably 0.05-:!% By mass.
- the insulin resistance ameliorating agent of the present invention can prevent and improve various diseases caused by insulin resistance, such as complications or treatment, and reduce the risk of complications such as these diseases. Is possible. Moreover, the insulin resistance improving agent of the present invention can be suitably used for patients whose insulin resistance is lower than that of healthy people. Insulin resistance is generally defined as a fasting plasma insulin level of 10 to 15 a U / m 1 or more and a HOMA index of 1.73 or more.
- Examples of various diseases caused by strength and insulin resistance include hypertension, hyperlipidemia, diabetes, arteriosclerosis and the like.
- complications caused by these diseases include i) stroke due to hypertension, nephrosclerosis, renal failure, and mouth) arteriosclerosis due to hyperlipidemia, Kneeitis, c) Diabetic retinopathy due to diabetes, nephropathy, neuropathy, diabetic gangrene, 2) Cardiovascular diseases such as stroke, cerebral infarction, angina pectoris and myocardial infarction due to arteriosclerosis, uremia, nephrosclerosis And nephropathy such as renal disease and renal failure can be exemplified.
- the present inventors have found that the compound of the present invention has an action of reducing hemoglobin Ale value and improving hyperglycemia (International Publication No. 2005Z095436). It is preferable that the disease to which the insulin resistance improving agent of the present invention is applied is not one in which the value of hemoglobin Ale is higher than that of a healthy person.
- the production-increase of adipocyte ability inducing insulin resistance such as TNF-a, MCP_1, and FFA is suppressed.
- adipocyte ability inducing insulin resistance such as TNF-a, MCP_1, and FFA.
- inflammatory diseases in various organs such as autoimmune diseases such as rheumatoid arthritis, Crohn's disease, nephritis, vaginitis, hepatitis, pneumonia, etc. It also has the effect of preventing and / or improving cachexia in vascular disorders, sepsis and malignant tumors.
- the insulin resistance-improving agent of the present invention is preferably used also for a patient in a state where the production of the adipocyte force-in is enhanced, particularly in a state where the production of adipocyte force-in causing insulin resistance is enhanced. Is possible.
- the administration time of the medicament of the present invention is not particularly limited, and can be appropriately selected according to the treatment method for the target disease.
- the dosage form is preferably determined according to the dosage form, the patient's age, sex, other conditions, the degree of symptoms of the patient, and the like.
- the dosage of the pharmaceutical agent of the present invention is appropriately selected depending on the usage, patient age, sex, disease severity, other conditions, and the like.
- the amount of the compound of the present invention as an active ingredient should be in the range of 0.001 to 50 mg / kg / day, preferably 0.01 to 1 mg / kgZ day.
- the dry mass of the extract etc. is 0.1 to 1000 mg / kg / ⁇ , preferably 1 to 100 mg / kg / ⁇ . It is good to use as a guide. In either case, it can be administered once or divided into several times a day.
- the compound of the present invention or a composition containing the compound can be contained in a food or drink (beverage or food) to obtain a food or drink having an effect of improving insulin resistance.
- a food or drink beverage or food
- the form and properties are not particularly limited, and the ingredients normally used for food and drink are usually used except that the active ingredient is contained. It can manufacture by the method of.
- the amount of the compound of the present invention or an extract containing the compound of the present invention contained in the food or drink of the present invention is not particularly limited and may be appropriately selected.
- the amount of the compound of the present invention the food or drink The content is at least 0.0001% by mass, preferably 0.001 to 1% by mass, particularly preferably 0.001 to 1% by mass.
- the food / beverage products of the present invention can be used for various purposes utilizing the insulin resistance improving effect.
- uses such as food / beverage products useful for reducing * removal of risk factors for lifestyle-related diseases thought to be caused by insulin resistance.
- the food and drink according to the present invention can prevent and reduce the risk of diseases caused by insulin resistance, such as hypertension, hyperlipidemia, and diabetes.
- the food and drink of the present invention has various complications resulting from insulin resistance, such as stroke due to high blood pressure, nephrosclerosis, renal failure or arteriosclerosis due to hyperlipidemia, knee inflammation, etc., diabetic retinopathy due to diabetes, Prevention of nephropathy, neuropathy, diabetic gangrene, stroke and cerebral infarction due to arteriosclerosis, cardiovascular diseases such as angina pectoris and myocardial infarction, nephropathy such as uremia, nephrosclerosis and renal failure And the risk can be reduced.
- the food and drink of the present invention is expected to have an effect of suppressing the production / increase of adipocyte power-in causing insulin resistance such as TNF-a, MCP-1, FFA, etc.
- adipocyte power-in causing insulin resistance
- diseases caused by increased adipocyte activity inflammatory diseases in various organs such as autoimmune diseases, rheumatoid arthritis, Crohn's disease, nephritis, knee inflammation, hepatitis, pneumonia, vascular disorders, sepsis, It also has the effect of preventing and reducing the risk of cachexia in malignant tumors.
- the food / beverage product of the present invention can be suitably ingested by a patient in a state in which the production of the adipocyte force-in is increased, particularly in a state in which the production of adipocyte force-in causing insulin resistance is increased. It is.
- the food / beverage product of the present invention is a food / beverage product with an indication that it is used to improve insulin resistance, for example, “insulin resistance improving effect displayed as“ improving insulin resistance ”.
- “Food and beverage containing compound” or “Table for improving insulin resistance” It is preferable to sell the food and drink containing the plant extract "," the food and drink containing the aloe vera extract described as for improving insulin resistance ", and the like.
- the indication of the improvement in insulin resistance is considered to have a meaning of enhancing insulin sensitivity. Therefore, the food and drink of the present invention can be displayed as “for insulin sensitivity enhancement”. That is, the display for improving insulin resistance may be such a display for “increasing insulin sensitivity”.
- the "display” means all actions for informing the consumer of the use, and if the display can recall the use, the purpose of the display, the display Regardless of the content, the object to be displayed, the medium, etc., all correspond to the “display” of the present invention. However, it is preferable to display it in such an expression that the consumer can directly recognize the use.
- the act of describing the above-mentioned use in the product or the product packaging relating to the food or drink of the present invention the product or the product packaging describing the above-mentioned use is transferred, and exhibited for delivery, transfer or delivery Display or distribute the above uses in the acts of importing, advertisements on products, price lists or transaction documents, or distributing them, or describing the above uses in the contents of these information (such as the Internet) ) Examples of activities provided by the method.
- the labeling is a labeling approved by the government or the like (for example, a labeling that is approved based on various systems determined by the government and is performed in a manner based on such approval).
- indications such as health foods, functional foods, enteral nutrition foods, special-purpose foods, nutritional functional foods, quasi-drugs, etc.
- Approved indications for example, indications approved by foods for specified health use and similar systems can be exemplified. Examples of the latter include labeling as food for specified health use, labeling as conditionally specified food for specified health use, labeling that affects the structure and function of the body, labeling for reducing disease risk, etc.
- the display can be listed as a typical example.
- the compound or composition of the present invention can be produced from a plant belonging to the family Liliaceae.
- production examples of 3-0- ⁇ -D-darcoviranosyl-4-methylergost-7-en-3-ol from aloe vera will be shown as production examples from plants belonging to the lily family.
- the insulin resistance improving action was evaluated by the insulin tolerance test shown in Example 3 to be described later. The results were the same as those for the ethyl acetate / butanol mixture extract. Since the action was confirmed, separation and purification of the components in this extract were attempted.
- the extract was subjected to thin layer chromatography (Merck, Silica Genole 60F254 and As a result of examination by RP-18F2543), it was considered that the separation method by normal phase silica gel column chromatography using a black mouthform / methanol mixture was appropriate. Therefore, 400 g of silica gel 60 (manufactured by Merck & Co., Inc.) was packed, and the column was poured with a solution prepared by dissolving 13 g of the extract in 1 ml of a chloroform / methanol mixture (1: 1) and adsorbed on the column.
- the yield of the crude product after removal of the solvent from each fraction was 1.44 g, 3.0 g, 1.17 g, 1.28 g, and 2.27 g, respectively.
- the crude product A was examined using thin layer chromatography (Merck, Silica Genole 60F254 and RP-18F2543).
- the separation method by reversed-phase silica gel column chromatography using was considered appropriate. Therefore, the crudely purified product A was dissolved in 1 ml of a mixed solution of chloroform / methanol (1: 1) and adsorbed onto a column packed with 180 g of Cosmo Seal 140 (manufactured by Nacalai Testa). The elution was performed sequentially with a 600% solution, 600 ml, and a methanol 95% solution 600 ml, methanol 100%, and 100 ml.
- the Rf value is very close to that of / 3-sitosterol darcoside. Therefore, it is a glycoside having a glycosyl S1 molecule bonded to the aglycone part. It was predicted. Furthermore, in order to examine the sugar composition of Compound 1, Compound 1 was subjected to methanolysis and then measured using GC-MS as a TMS derivative. As a result, the main peaks when the TMS derivative of the sugar moiety of Compound 1 was measured were observed at retention times of 14.28 minutes, 14.61 minutes, and 16.34 minutes. The main peaks of 14.27 minutes, 14.60 minutes, and 16.33 minutes. Also a standard galacto The peak corresponding to the main peak of the sesame (Kishida) and the standard xylose (Kishida) was not observed. Therefore, it was confirmed that the type of sugar contained in Compound 1 was glucose.
- Aloe vera mesophyll (transparent gel part) was dried by heating, ground into 0.3 g of dried aloe vera powder, 60 ml of 60%, 80%, or 100% ethanol was calcined and then heated at 60 ° C for 1 hour. . The extract was centrifuged at 1500 rpm for 20 minutes, and the supernatant was concentrated under reduced pressure to completely remove ethanol to obtain a crude extract. The dry weights of the crude extracts obtained by extraction with 60%, 80% and 100% ethanol were 65 mg, 42 mg and 18 mg, respectively. It was confirmed by thin layer chromatography that these crude extracts contained 3_0_ ⁇ _D_darcobilanosyl_4-methylergosto-1-en-3_ol.
- the aloe vera mesophyll (transparent gel part) was dried by heating, and after adding 60 ml of water to 0.3 g of the pulverized dried aloe vera powder, the mixture was heated to reflux at 95 ° C for 5 hours.
- the extract was centrifuged at 1500i "pm for 20 minutes, and the supernatant was lyophilized to obtain 75 mg of crude extract.
- This crude extract was 3 -0- ⁇ -D-Darcopyranosyl 4-methyl ergost. It was confirmed by thin layer chromatography that it contained 1-7-en-3-ol.
- Aloe vera mesophyll (transparent gel part) is dried by heating and pulverized 21 kg of dried aloe vera powder, 90 liters of black mouth form / methanol mixture (2: 1) is added, and then immersed at room temperature and filtered. Then, 90 liters of a chloroform-form / methanol mixture (2: 1) was again added to the filtration residue, and the same operation was repeated 4 times. The obtained filtrate (350 liters) was concentrated at 28 ° C to finally obtain 784 g of a crude extract.
- the silica gel column [glass column: 70 mm X 500 mm, Filler: SP_60—40 / 60 (manufactured by Daiso Co., Ltd.)], and a black mouth form / methanol mixture (20: 1) 10 litter, a black mouth form / methanol mixture (10: 1) 10 liters was used as an elution solvent, and the elution was carried out sequentially under the conditions of pressure: lOkgf cm- 2 and flow rate: 40 ml / min.
- ZDF Korean Diabetes model animal exhibiting insulin resistance.
- Diabetic Fatty rats were used to evaluate the change in the amount of free fatty acid (FFA) in serum by the insulin resistance improving agent of the present invention.
- FFA free fatty acid
- Table 1 shows the concentration of free fatty acids in rat serum 45 days after the start of administration.
- the serum free fatty acid level is approximately 53 in the test sample administration group compared to the negative sample administration group. A significant decrease was observed at / 0 . During the administration period, no side effects from pathological findings were observed.
- the p-value in the table indicates the significance probability according to Tukey-Kramer's test.
- ZDF Korean diabetes model animal showing insulin resistance.
- Diabetic Fatty rats were used to evaluate the effects of the insulin resistance improving agent of the present invention on the production of TNF-spleen and MCP-1 from each cell in the adipose tissue.
- Example 2 For the sample of Example 2, the same test sample and negative sample as those prepared in Example 1 were used.
- Table 2 shows TNF production from adipose tissue.
- Table 3 also shows the amount of MCP_1 produced.
- the TNF_ ⁇ and MCP-1 groups showed a significant production inhibitory effect in the group that received the test sample compared to the negative sample administration group.
- the administration of the insulin resistance improving agent of the present invention reduces the production of adipocyte force-in that causes insulin resistance in adipose tissue that exacerbates insulin resistance. It became clear that it had the effect of preventing the deterioration of resistance.
- the ⁇ value in the table indicates the significance probability by Tukey-Kramer's test.
- an insulin tolerance test was performed using ZDF (Zucker Diabetic Fatty) rats, which are obese diabetes model animals exhibiting insulin resistance, whereby the insulin sensitivity of the insulin resistance-improving agent of the present invention was measured. This was done to confirm the enhancement effect of.
- ZDF Zinc Diabetic Fatty
- Example 3 For the sample of Example 3, the same test sample and negative sample as those prepared in Example 1 or 2 were used.
- FIG. Figure 1 shows the results of the insulin tolerance test.
- the blood glucose level of the group receiving the test sample is lower than that of the group receiving the negative sample at any time point from 15 minutes to 60 minutes after the start of insulin administration. It became clear. From the results of this example, it was found that administration of the insulin resistance improving agent of the present invention enhances insulin sensitivity.
- the present invention relates to a safe insulin resistance ameliorating agent capable of enhancing insulin sensitivity without side effects, and a functional food or drink such as a food for specified health use containing the insulin resistance ameliorating agent. Improvement or prevention of diseases, complications, etc. caused by decreased insulin sensitivity, such as hypertension, diabetes, hyperlipidemia, arteriosclerosis, and complications of these diseases It also has the effect of reducing such risks.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007539847A JP4169777B2 (ja) | 2005-09-30 | 2006-09-22 | インスリン抵抗性改善剤 |
AU2006300637A AU2006300637C1 (en) | 2005-09-30 | 2006-09-22 | Agent for improving insulin resistance |
EP06810422.3A EP1930013B1 (en) | 2005-09-30 | 2006-09-22 | Agent for improving insulin resistance |
US11/916,008 US8236769B2 (en) | 2005-09-30 | 2006-09-22 | Agent for improving insulin resistance |
CA2613041A CA2613041C (en) | 2005-09-30 | 2006-09-22 | Agent for improving insulin resistance |
ES06810422.3T ES2575515T3 (es) | 2005-09-30 | 2006-09-22 | Agente para mejorar la resistencia a la insulina |
CN2006800355318A CN101272795B (zh) | 2005-09-30 | 2006-09-22 | 胰岛素抵抗改善剂 |
HK09100023.2A HK1122985A1 (en) | 2005-09-30 | 2009-01-02 | Agent for improving insulin resistance |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-287884 | 2005-09-30 | ||
JP2005287884 | 2005-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007043302A1 true WO2007043302A1 (ja) | 2007-04-19 |
Family
ID=37942553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/318809 WO2007043302A1 (ja) | 2005-09-30 | 2006-09-22 | インスリン抵抗性改善剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8236769B2 (ja) |
EP (1) | EP1930013B1 (ja) |
JP (1) | JP4169777B2 (ja) |
KR (1) | KR100941016B1 (ja) |
CN (1) | CN101272795B (ja) |
AU (1) | AU2006300637C1 (ja) |
CA (1) | CA2613041C (ja) |
ES (1) | ES2575515T3 (ja) |
HK (1) | HK1122985A1 (ja) |
RU (1) | RU2379037C2 (ja) |
WO (1) | WO2007043302A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058794A1 (ja) * | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101212979B (zh) * | 2005-09-22 | 2013-07-17 | 森永乳业株式会社 | 内脏脂肪蓄积抑制剂 |
ES2719098T3 (es) * | 2008-11-19 | 2019-07-08 | Morinaga Milk Industry Co Ltd | Composiciones que comprenden un lofenol |
LT2900230T (lt) | 2012-09-27 | 2019-01-10 | The Children`S Medical Center Corporation | Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai |
CA3044998A1 (en) * | 2014-03-26 | 2015-10-01 | The Children's Medical Center Corporation | Celastrol and derivatives for the treatment of obesity |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036283A (ja) * | 1996-07-18 | 1998-02-10 | Ichimaru Pharcos Co Ltd | 線維芽細胞増殖促進剤 |
JP2000319190A (ja) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | 肥満の予防改善剤 |
JP2003286185A (ja) * | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
WO2005095436A1 (ja) | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 4-メチルエルゴスト-7-エン-3-オール骨格を有する配糖体及び高血糖改善剤 |
WO2005094838A1 (ja) * | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
WO2006035525A1 (ja) * | 2004-09-29 | 2006-04-06 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60214741A (ja) * | 1984-04-05 | 1985-10-28 | Toyo Yakushiyoku Kogyo Kk | 血糖降下剤 |
JP3862295B2 (ja) | 1993-09-30 | 2006-12-27 | 独立行政法人理化学研究所 | 抗肥満剤 |
JPH0812573A (ja) | 1994-06-24 | 1996-01-16 | Mitsubishi Chem Corp | 遊離脂肪酸低下剤 |
JP3685833B2 (ja) | 1995-02-06 | 2005-08-24 | 日本メナード化粧品株式会社 | 免疫抑制改善剤 |
JPH10298100A (ja) | 1997-05-06 | 1998-11-10 | Mitsubishi Chem Corp | インスリン抵抗性に起因する疾患の予防及び/又は治療剤 |
JP3873097B2 (ja) | 1997-11-06 | 2007-01-24 | 独立行政法人理化学研究所 | 抗肥満剤及び脂質代謝改善剤 |
JP3858055B2 (ja) | 2000-02-29 | 2006-12-13 | 独立行政法人理化学研究所 | 抗肥満剤及び脂質代謝改善剤 |
JP2001247473A (ja) | 2000-03-06 | 2001-09-11 | Kao Corp | インスリン抵抗性改善剤 |
JP2002193797A (ja) | 2000-12-22 | 2002-07-10 | Mitsukan Group Honsha:Kk | インスリン抵抗性改善用組成物 |
US20060199761A1 (en) | 2002-01-31 | 2006-09-07 | Japan Science And Technology Agency | Insulin resistance improving agent |
US6884783B2 (en) * | 2002-05-03 | 2005-04-26 | Unigen Pharmaceuticals, Inc. | 7-Hydroxy chromones as potent antioxidants |
JP4846990B2 (ja) | 2003-08-06 | 2011-12-28 | 株式会社テラ・ブレインズ | アディポネクチン分泌促進剤 |
-
2006
- 2006-09-22 WO PCT/JP2006/318809 patent/WO2007043302A1/ja active Application Filing
- 2006-09-22 ES ES06810422.3T patent/ES2575515T3/es active Active
- 2006-09-22 JP JP2007539847A patent/JP4169777B2/ja active Active
- 2006-09-22 CN CN2006800355318A patent/CN101272795B/zh active Active
- 2006-09-22 US US11/916,008 patent/US8236769B2/en active Active
- 2006-09-22 AU AU2006300637A patent/AU2006300637C1/en active Active
- 2006-09-22 RU RU2007143530/04A patent/RU2379037C2/ru not_active IP Right Cessation
- 2006-09-22 CA CA2613041A patent/CA2613041C/en active Active
- 2006-09-22 KR KR1020077028132A patent/KR100941016B1/ko active IP Right Grant
- 2006-09-22 EP EP06810422.3A patent/EP1930013B1/en active Active
-
2009
- 2009-01-02 HK HK09100023.2A patent/HK1122985A1/xx not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036283A (ja) * | 1996-07-18 | 1998-02-10 | Ichimaru Pharcos Co Ltd | 線維芽細胞増殖促進剤 |
JP2000319190A (ja) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | 肥満の予防改善剤 |
JP2003286185A (ja) * | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
WO2005095436A1 (ja) | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 4-メチルエルゴスト-7-エン-3-オール骨格を有する配糖体及び高血糖改善剤 |
WO2005094838A1 (ja) * | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
WO2006035525A1 (ja) * | 2004-09-29 | 2006-04-06 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
Non-Patent Citations (7)
Title |
---|
OKYAR A. ET AL.: "Effect of Aloe vera leaves on blood glucose level in type I and type II diabetic rat models", PHYTOTHER. RES., vol. 15, no. 2, 2001, pages 157 - 161, XP003011588 * |
PANOSYAN A.G. ET AL.: "Sterols and sterol glycosides of Bryonia alba", KHIMIYA PRIRODNYKH SOEDINENII, no. 3, 1977, pages 353 - 360, XP003010652 * |
RAJASEKARAN S. ET AL.: "Hypoglycemic Effect of Aloe vera gel on streptozotocin-induced diabetes in experimental rats", JOURNAL OF MEDICINAL FOOD, vol. 7, no. 1, 2004, pages 61 - 66, XP003011589 * |
See also references of EP1930013A4 * |
TANAKA M. ET AL.: "Identification of Five Phytosterols from Aloe Vera Gels as Anti-diabetic Compounds", BIOL. PHARM. BULL., vol. 26, no. 7, July 2006 (2006-07-01), pages 1418 - 1422, XP003011592 * |
YEH G.Y. ET AL.: "Systematic review of herbs and dietary supplements for glycemic control in diabetes", DIABETES CARE, vol. 26, no. 4, 2003, pages 1277 - 1294, XP003011591 * |
YONGCHAIYUDHA S. ET AL.: "Antidiabetic activity of Aloe vera L.juice. I. Clinical trial in new cases of diabetes mellitus", PHYTOMEDICINE, vol. 3, no. 3, 1996, pages 241 - 243, XP003011590 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058794A1 (ja) * | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
JP4580041B2 (ja) * | 2008-11-19 | 2010-11-10 | 森永乳業株式会社 | 抗酸化剤 |
JPWO2010058794A1 (ja) * | 2008-11-19 | 2012-04-19 | 森永乳業株式会社 | 抗酸化剤 |
RU2465909C1 (ru) * | 2008-11-19 | 2012-11-10 | Моринага Милк Индастри Ко., Лтд. | Антиоксидант |
AU2009318455B2 (en) * | 2008-11-19 | 2012-11-29 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
US8486899B2 (en) | 2008-11-19 | 2013-07-16 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
KR101331772B1 (ko) * | 2008-11-19 | 2013-11-22 | 모리나가 뉴교 가부시키가이샤 | 항산화제 |
Also Published As
Publication number | Publication date |
---|---|
AU2006300637C1 (en) | 2010-07-01 |
EP1930013A1 (en) | 2008-06-11 |
KR100941016B1 (ko) | 2010-02-05 |
CN101272795B (zh) | 2013-04-03 |
AU2006300637A1 (en) | 2007-04-19 |
ES2575515T3 (es) | 2016-06-29 |
JPWO2007043302A1 (ja) | 2009-04-16 |
JP4169777B2 (ja) | 2008-10-22 |
KR20080016827A (ko) | 2008-02-22 |
CA2613041A1 (en) | 2007-04-19 |
CA2613041C (en) | 2012-03-06 |
HK1122985A1 (en) | 2009-06-05 |
EP1930013A4 (en) | 2010-01-13 |
AU2006300637B2 (en) | 2009-12-10 |
RU2007143530A (ru) | 2009-06-27 |
US8236769B2 (en) | 2012-08-07 |
US20090312275A1 (en) | 2009-12-17 |
RU2379037C2 (ru) | 2010-01-20 |
CN101272795A (zh) | 2008-09-24 |
EP1930013B1 (en) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4176140B2 (ja) | インスリン抵抗性改善剤 | |
JP4165658B2 (ja) | インスリン抵抗性改善剤 | |
US8486462B2 (en) | Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent | |
WO2007043302A1 (ja) | インスリン抵抗性改善剤 | |
JP4162703B2 (ja) | 内臓脂肪蓄積抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680035531.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007539847 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007143530 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006810422 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11916008 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5514/CHENP/2007 Country of ref document: IN Ref document number: 1020077028132 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006300637 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2613041 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006300637 Country of ref document: AU Date of ref document: 20060922 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006300637 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |